Italy Takes Global Lead in Pricing Transparency by Forcing Pharma…
In July 2020, Italy became the first country in the world to mandate pharma companies to disclose data surrounding public subsidies received for the…
Tagged with Pricing
Supporting Value-Based Purchasing in the US Through Changes in…
Michael Ciarametaro, VP for Research at the US National Pharmaceutical Council (NPC), outlines issues surrounding the outdated Medicaid Best Price…
Overcoming US Pricing & Reimbursement Challenges
Executives from ALK, Sanofi Genzyme and Novartis discuss how they are navigating pricing and reimbursement issues in the USA, home to the world’s…
Chinese Biotechs’ Domestic Pricing Strategies
Alphamab Oncology and I-Mab Biopharma, two of China’s fastest-growing biotech firms, both bolstered by recent successful IPOs, are increasingly…
Drugmakers Push Back Against Canada’s New Pricing…
Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory body to reconsider their…
Schalk Opperman – General Manager, Merck Romania
Schalk Opperman, general manager of Merck Romania explains the key factors behind successful product launches in what is an unpredictable market. He…
The US Healthcare Insurance Industry Hits Back
In 2019, several drug companies testified to the US Senate Finance Committee on medicine price hikes with a narrative of discounts given to health…
Martin Mátl – Executive Director, ČAFF, Czech Republic
Martin Mátl, executive director of the Czech Association of Pharmaceutical Companies (ČAFF), shares the key priorities and challenges of the…
Chinese Pharma’s Latest Race to the Bottom on Pricing
China’s roll-out of a 25-province expansion to the 4+7 pilot procurement scheme has seen pharma companies scrambling to cut prices for their…
ICER Strikes Again: Scandal Time?
The US drug-price watchdog, The Institute for Clinical & Economic Review (ICER) recently issued a “Report on Unsupported Price Increases“,…
The USA’s Safe Importation Action Plan: Trump’s Pharma…
In a bid to make tangible progress on the issue of lowering prescription drug pricing before the 2020 presidential election, the Trump administration…
Making the Case for Competition — With Data
Generic drugs foster competition in the pharmaceutical market. Chester “Chip” Davis, Jr. of the Association for Accessible Medicines (AAM)…
